» Articles » PMID: 28754676

Inactivation and Mutation Drive a Convergence Toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas

Abstract

Extensive dysregulation of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through next-generation sequencing. However, a scientific understanding of the cross-talk between epigenetic and genomic aberrations remains limited. Here we identify three ccRCC epigenetic clusters, including a clear cell CpG island methylator phenotype (C-CIMP) subgroup associated with promoter methylation of VEGF genes (, and ). C-CIMP was furthermore characterized by silencing of genes related to vasculature development. Through an integrative analysis, we discovered frequent silencing of the histone H3 K36 methyltransferase as the sole chromatin-modifying gene silenced by DNA methylation in ccRCC. Notably, tumors harboring methylation were of higher grade and stage in different ccRCC datasets. promoter methylation correlated with somatic mutations across and within spatially distinct regions of primary ccRCC tumors. ccRCC harboring epigenetic silencing of displayed a specific genome-wide methylome signature consistent with the mutation methylome signature observed in Sotos syndrome. Thus, we concluded that epigenetic silencing of genes involved in angiogenesis is a hallmark of the methylator phenotype in ccRCC, implying a convergence toward loss of function of epigenetic writers of the H3K36 histone mark as a root feature of aggressive ccRCC. .

Citing Articles

Impact of NSD1 Alternative Transcripts in Actin Filament Formation and Cellular Division Pathways in Fibroblasts.

Conteduca G, Cangelosi D, Baldo C, Arado A, Testa B, Wagner R Genes (Basel). 2024; 15(9).

PMID: 39336709 PMC: 11431170. DOI: 10.3390/genes15091117.


Identification of a signature of histone modifiers in kidney renal clear cell carcinoma.

Huang Y, Yang Z, Tang Y, Chen H, Liu T, Peng G Aging (Albany NY). 2024; 16(12):10489-10511.

PMID: 38888515 PMC: 11236308. DOI: 10.18632/aging.205944.


Macrophage-derived ectosomal miR-350-3p promotes osteoarthritis progression through downregulating chondrocyte H3K36 methyltransferase NSD1.

Lin R, Yin J, Huang J, Zou L, Liu L, Tang W Cell Death Discov. 2024; 10(1):223.

PMID: 38719811 PMC: 11078928. DOI: 10.1038/s41420-024-01986-5.


Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.

Lu X, Vano Y, Su X, Helleux A, Lindner V, Mouawad R Cell Rep Med. 2023; 4(11):101287.

PMID: 37967556 PMC: 10694769. DOI: 10.1016/j.xcrm.2023.101287.


Establishment of a new prognostic risk model of GNG7 pathway-related molecules in clear cell renal cell carcinoma based on immunomodulators.

Zheng J, Zhang W, Zhang J BMC Cancer. 2023; 23(1):864.

PMID: 37704946 PMC: 10500784. DOI: 10.1186/s12885-023-11265-8.


References
1.
Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J . Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nat Genet. 2015; 47(10):1149-57. PMC: 4780747. DOI: 10.1038/ng.3385. View

2.
Berdasco M, Ropero S, Setien F, Fraga M, Lapunzina P, Losson R . Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A. 2009; 106(51):21830-5. PMC: 2793312. DOI: 10.1073/pnas.0906831106. View

3.
Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

4.
Fay A, de Velasco G, Ho T, Van Allen E, Murray B, Albiges L . Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016; 14(7):820-4. PMC: 5582541. DOI: 10.6004/jnccn.2016.0086. View

5.
Sankin A, Hakimi A, Mikkilineni N, Ostrovnaya I, Silk M, Liang Y . The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med. 2014; 3(6):1485-92. PMC: 4298374. DOI: 10.1002/cam4.293. View